Treatment of opioid use disorder among commercially insured patients in context of COVID-19 pandemic


What The Study Did:

Opioid use disorder treatment during the early months of the COVID-19 pandemic, including medication fills, outpatient visits and urine tests among privately insured individuals, was compared with 2019 in this study.


Authors:

Haiden A. Huskamp, Ph.D., of Harvard Medical School in Boston, is the corresponding author.


To access the embargoed study:

Visit our For The Media website at this link

https:/

/

media.

jamanetwork.

com/

(doi:10.1001/jama.2020.21512)


Editor’s Note:

The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #


Media advisory:

The full study is linked to this news release.


Embed this link to provide your readers free access to the full-text article

This link will be live at the embargo time

https:/

/

jamanetwork.

com/

journals/

jama/

fullarticle/

10.

1001/

jama.

2020.

21512?guestAccessKey=

07d7e6a6-d1c1-4ab2-a9a8-220eeb6674e2&utm_source=

For_The_Media&utm_medium=

referral&utm_campaign=

ftm_links&utm_content=

tfl&utm_term=

121520

###

This part of information is sourced from https://www.eurekalert.org/pub_releases/2020-12/jn-too_1121020.php

withyou android app